within Pharmacolibrary.Drugs.ATC.D;

model D06BB07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D06BB07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lysozyme is an enzyme with antibacterial properties, primarily used as a topical agent in the treatment of infectious skin diseases. It is classified in the ATC system as D06BB07. Historically, it has been used in various forms for wound healing and skin infection management, but it is not widely approved as a systemically administered drug in modern medicine.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models with specific parameters available for topical or systemic lysozyme in humans. The following are estimated parameters based on general peptide/protein pharmacokinetics and the molecular properties of lysozyme.</p><h4>References</h4><ol><li><p>Nagai, J, et al., &amp; Takano, M (2002). Effect of gentamicin on pharmacokinetics of lysozyme in rats: interaction between megalin substrates in the kidney. <i>The Journal of pharmacy and pharmacology</i> 54(11) 1491–1496. DOI:<a href=\"https://doi.org/10.1211/00223570272\">10.1211/00223570272</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12495551/\">https://pubmed.ncbi.nlm.nih.gov/12495551</a></p></li><li><p>Dolman, ME, et al., &amp; Kok, RJ (2012). Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 157(3) 461–468. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2011.08.041\">10.1016/j.jconrel.2011.08.041</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21911014/\">https://pubmed.ncbi.nlm.nih.gov/21911014</a></p></li><li><p>Ronca, F, et al., &amp; Ronca, G (1998). Anti-inflammatory activity of chondroitin sulfate. <i>Osteoarthritis and cartilage</i> 6 Suppl A 14–21. DOI:<a href=\"https://doi.org/10.1016/s1063-4584(98)80006-x\">10.1016/s1063-4584(98)80006-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9743814/\">https://pubmed.ncbi.nlm.nih.gov/9743814</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D06BB07;
